Cellular and Molecular Gastroenterology and Hepatology (Jan 2017)

Targeted Inhibition of Pancreatic Acinar Cell Calcineurin Is a Novel Strategy to Prevent Post-ERCP PancreatitisSummary

  • Abrahim I. Orabi,
  • Li Wen,
  • Tanveer A. Javed,
  • Tianming Le,
  • Ping Guo,
  • Subramaniam Sanker,
  • David Ricks,
  • Kristy Boggs,
  • John F. Eisses,
  • Carlos Castro,
  • Xiangwei Xiao,
  • Krishna Prasadan,
  • Farzad Esni,
  • George K. Gittes,
  • Sohail Z. Husain

Journal volume & issue
Vol. 3, no. 1
pp. 119 – 128

Abstract

Read online

Background & Aims: There is a pressing need to develop effective preventative therapies for post–endoscopic retrograde cholangiopancreatography pancreatitis (PEP). We showed that early PEP events are induced through the calcium-activated phosphatase calcineurin and that global calcineurin deletion abolishes PEP in mice. A crucial question is whether acinar cell calcineurin controls the initiation of PEP in vivo. Methods: We used a mouse model of PEP and examined the effects of in vivo acinar cell-specific calcineurin deletion by either generating a conditional knockout line or infusing a novel adeno-associated virus–pancreatic elastase improved Cre (I–iCre) into the pancreatic duct of a calcineurin floxed line. Results: We found that PEP is dependent on acinar cell calcineurin in vivo, and this led us to determine that calcineurin inhibitors, infused within the radiocontrast, largely can prevent PEP. Conclusions: These results provide the impetus for launching clinical trials to test the efficacy of intraductal calcineurin inhibitors to prevent PEP. Keywords: Adeno-Associated Virus, Calcineurin B1, FK506, Cyclosporine A, Intraductal Delivery